Prothena Corporation Investor Relations Material
Latest events
Q4 2023
Prothena Corporation
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Prothena Corporation plc
Access all reports
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies for diseases caused by protein dysregulation. The company's portfolio includes a range of investigational humanized antibodies and other therapeutic candidates targeting conditions such as AL amyloidosis, Parkinson's disease, ATTR amyloidosis, and Alzheimer's disease. Prothena's approach leverages insights into the biology of misfolded proteins to develop therapies aimed at changing the course of neurodegenerative and rare peripheral amyloid diseases. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.
Key slides for Prothena Corporation plc
Q4 2023
Prothena Corporation plc
Q4 2023
Prothena Corporation plc
Latest articles
Master of Tickets: Breaking Down Live Nation Entertainment
Since merging in 2010, Ticketmaster and Live Nation have built an expansive ecosystem that dominates global live entertainment.
6 Dec 2024
Peter Beck: The Innovator at Rocket Lab
Peter Beck, born and raised in New Zealand, is one of the key individuals in the aerospace industry as the founder and CEO of Rocket Lab.
6 Dec 2024
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
Ticker symbol
PRTA
Country
🇺🇸 United States